

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2017

**THE CLOROX COMPANY**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation)

1-07151  
(Commission File Number)

31-0595760  
(I.R.S. Employer  
Identification No.)

**1221 Broadway, Oakland, California 94612-1888**  
(Address of principal executive offices) (Zip code)

**(510) 271-7000**  
(Registrant's telephone number, including area code)

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 7.01 Regulation FD Disclosure**

On August 22, 2017, The Company announced that it has sold the Aplicare skin antiseptics business. The transaction closed on August 21, 2017. The full text of the press release related to the sale is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits****(d) Exhibits**

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release dated August 22, 2017 of The Clorox Company

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CLOROX COMPANY

Date: August 23, 2017

By: /s/ Laura Stein

Executive Vice President –

General Counsel and Corporate Affairs

---

THE CLOROX COMPANY

FORM 8-K

INDEX TO EXHIBITS

<b>Exhibit</b>	<b>Description</b>
<a href="#">99.1</a>	<a href="#">Press Release dated August 22, 2017 of The Clorox Company</a>

---

## The Clorox Company Sells Aplicare to Medline Industries

OAKLAND, Calif., Aug. 22, 2017 – The Clorox Company (NYSE: CLX) announced today that it has sold the Aplicare skin antiseptics business to Medline Industries, the leading privately held manufacturer and distributor of health care supplies in the U.S. The transaction closed on Aug. 21.

“Selling Aplicare, which was part of our Professional Products business, was the result of our periodic strategic assessment of our global portfolio,” said Clorox Chairman and CEO Benno Dorer. “We are very pleased that, in Medline, we’ve found a buyer that has strong capabilities and can add significant value to the Aplicare business.”

Dorer added, “Importantly, this doesn’t change the strategic focus of our Professional Products business, which continues to be stopping the spread of infection, with an emphasis on killing pathogens in the environment.”

As communicated in the company’s fiscal year 2017 SEC filings, Clorox had been exploring strategic alternatives for Aplicare. Clorox’s Form 10-K filing on Aug. 15 reported that for fiscal year 2017, which ended June 30, 2017, the Aplicare business had \$46 million in net sales, representing slightly less than 1 percent of total company sales, and insignificant net earnings.

Clorox will provide an updated fiscal year 2018 outlook during its first-quarter fiscal year 2018 earnings call on Nov. 1.

### The Clorox Company

The Clorox Company (NYSE: CLX) is a leading multinational manufacturer and marketer of consumer and professional products with more than 8,000 employees worldwide and fiscal year 2017 sales of \$6 billion. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products; Pine-Sol<sup>®</sup> cleaners; Liquid Plumr<sup>®</sup> clog removers; Poett<sup>®</sup> home care products; Fresh Step<sup>®</sup> cat litter; Glad<sup>®</sup> bags, wraps and containers; Kingsford<sup>®</sup> charcoal; Hidden Valley<sup>®</sup> dressings and sauces; Brita<sup>®</sup> water-filtration products; Burt’s Bees<sup>®</sup> natural personal care products; and RenewLife<sup>®</sup> digestive health products. The company also markets brands for professional services, including Clorox Healthcare<sup>®</sup> and Clorox Commercial Solutions<sup>®</sup>. More than 80 percent of the company’s sales are generated from brands that hold the No. 1 or No. 2 market share positions in their categories.

Clorox is a signatory of the United Nations Global Compact, a community of global leaders committed to sustainability. The company also has been broadly recognized for its corporate responsibility efforts, most notably receiving a Safer Choice Partner of the Year Award in 2016 and 2017 from the U.S. Environmental Protection Agency as well as being named to CR Magazine’s 2017 Best Corporate Citizens list and included in the 2016 Newsweek Green Rankings. The Clorox Company and its foundations contributed about \$11 million in combined cash grants, product donations and cause marketing in fiscal year 2017. For more information, visit [TheCloroxCompany.com](http://TheCloroxCompany.com), including the Good Growth blog, and follow the company on Twitter at [@CloroxCo](https://twitter.com/CloroxCo).

### Clorox Media Relations

**Aileen Zerrudo**, 510-271-3075  
[aileen.zerrudo@clorox.com](mailto:aileen.zerrudo@clorox.com)

**Kathryn Caulfield** 510-271-7209  
[kathryn.caulfield@clorox.com](mailto:kathryn.caulfield@clorox.com)

### Clorox Investor Relations

Lisah Burhan 510-271-3269, [lisah.burhan@clorox.com](mailto:lisah.burhan@clorox.com)  
Steve Austenfeld 510-271-2270, [steve.austenfeld@clorox.com](mailto:steve.austenfeld@clorox.com)

### Medline Media Relations

**Blair Klein**, 847-643-3308  
[bklein@medline.com](mailto:bklein@medline.com)

---